Cannabis-Based Medicines for Chronic Neuropathic Pain in Adults
The 2025 Cochrane review on cannabis-based medicines neuropathic pain provides the most rigorous analysis of cannabinoid effectiveness for chronic nerve pain. This systematic review update incorporates recent trial data to inform evidence-based clinical…
Medical marijuana for management of cancer pain: a narrative review.
A 2025 narrative review examines medical marijuana cancer pain management across 20 recent studies. It highlights ongoing knowledge gaps despite expanding legal access. The review consolidates current research trends on medical marijuana cancer pain…
Psychological and Psychosocial Interventions for Schizophrenia with Substance Use Disorders
This systematic review examines schizophrenia dual diagnosis treatment focusing on psychological and psychosocial interventions. It addresses a critical gap for patients with co-occurring substance use disorders. The research highlights the challenges…
Effects of Prescribed Medical Cannabis on Driving: Study Protocol Analysis
Australian researchers have developed a medical cannabis driving safety protocol to assess real-world driving performance in patients using prescribed THC. This two-phase trial aims to provide critical evidence on driving safety for medical cannabis…
Medical Cannabis for the Treatment of Peripheral Neuropathy due to Diabetes: A Systematic Review
This systematic review highlights cannabinoids diabetic neuropathy pain relief, showing significant benefits in three of four trials. THC-containing products demonstrated the strongest efficacy for diabetic nerve pain. These findings provide…
The efficacy and safety of cannabinoids for mental and substance use disorders: a systematic review and meta-analysis
A landmark cannabinoids mental health disorders systematic review published in The Lancet Psychiatry examines cannabinoids for mental health and substance use disorders. This comprehensive analysis addresses critical evidence gaps. The findings directly…
Effect of Glucagon-Like-Peptide-1 Receptor Agonists on Neuropsychiatric Outcomes
This meta-analysis examines GLP-1 receptor agonists neuropsychiatric effects across 82 studies. Evidence suggests potential benefits including Parkinson's disease risk reduction. However, the quality of evidence limits clinical recommendations beyond…
Why Averages Fail Palliative Cannabis Patients – A New Framework
Randomized controlled trials often fail to capture what palliative care cannabis patients actually experience. A new contextual effectiveness framework argues that averaging subjective outcomes obscures genuine individual benefit. This Evidence Brief…
In the Mix: 11 More Articles — April 26, 2026
This review highlights cannabis clinical relevance April 26 2026, focusing on product quality and regulatory updates. It covers wellness trends and clinical insights from recent articles. Clinicians will find valuable information for patient care and…
Group Seeks Court Order to Halt CMS Medicare THC Hemp Marijuana Program
The CMS hemp pilot lawsuit highlights a legal challenge affecting Medicare cannabinoid coverage. This case could reshape access to cannabis-derived products for Medicare patients. Clinicians should monitor this lawsuit closely due to its impact on…